Form 4: InMed Pharmaceuticals Director Janet Grove Acquires Stock Options

Director Janet Grove of InMed Pharmaceuticals Inc. was granted 550 stock options on December 20, 2024, which will vest on December 19, 2025, or immediately prior to the next Annual General Meeting, whichever is sooner.

Summary

• Janet Grove, a director at InMed Pharmaceuticals Inc., was granted 550 employee stock options on December 20, 2024.
• These options have an exercise price of $4.14 per share.
• The options will vest 100% on December 19, 2025, or immediately prior to the next Annual General Meeting, whichever is sooner.
• The underlying security for these options is 550 common shares.
• Following the transaction, Ms. Grove directly owns 975 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a director, which is generally viewed as a positive sign of alignment between management and shareholders. There is no indication of any negative sentiment.

Positives

• The granting of stock options to a director aligns their interests with the company's performance and shareholder value.

Industry Context

Stock option grants to directors are a common practice in publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly listed companies, similar to practices at companies like Amgen, Biogen, and Gilead Sciences.
• The vesting period of one year is also a common practice, aligning with typical industry standards for equity-based compensation.

Stakeholder Impact

• The granting of stock options to a director can be seen as a positive sign by shareholders, as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director, insider trading, InMed Pharmaceuticals, equity, vesting